Reviva Pharmaceuticals I...

0.56
-0.39 (-41.29%)
At close: Apr 01, 2025, 1:50 PM
-41.29%
Bid 0.56
Market Cap 26.11M
Revenue (ttm) n/a
Net Income (ttm) -46M
EPS (ttm) -1.08
PE Ratio (ttm) -0.52
Forward PE -2.19
Analyst Buy
Ask 0.56
Volume 4,105,720
Avg. Volume (20D) 1,467,243
Open 0.94
Previous Close 0.95
Day's Range 0.55 - 0.95
52-Week Range 0.55 - 4.28
Beta -0.10

About RVPH

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 18, 2018
Employees 15
Stock Exchange NASDAQ
Ticker Symbol RVPH
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for RVPH stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 1594.61% from the latest price.

Stock Forecasts
1 hour ago
Reviva Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription
3 months ago
-39.13%
Reviva Pharmaceuticals shares are trading lower after the company announced a $18 million public offering.